Literature DB >> 18835778

Percutaneous excisional biopsy of impalpable breast lesions under ultrasound visualization.

Qingqing He1, Xihong Fan, Yifan Guan, Jun Tian, Ziyi Fan, Luming Zheng.   

Abstract

Within the last ten years, the development of innovative minimally invasive breast biopsy technologies has made a significant impact on the diagnostic evaluation of impalpable breast lesions. The Mammotome minimally invasive biopsy system is a diagnostic tool used under stereotactic or ultrasound guidance. The minimally invasive biopsies for 143 impalpable breast lesions in 86 patients were performed using the B-ultrasound-guided 8-gauge vacuum-assisted Mammotome system at Jinan Military General Hospital. One hundred and forty-three breast lesions in 86 patients were excised completely using this method. The average biopsy procedure time was 17 min (range, 3-45 min). Clinically, suspicious lesions were satisfactorily confirmed by this system. One hundred and twenty-one lesions were diagnosed as fibroadenoma, nineteen lesions as breast adenosis, one lesion as invasive breast cancer, and two lesions as ductal carcinoma in situ. Skin ecchymosis was found in two patients. One hundred and thirty-two impalpable lesions were completely excised, as demonstrated by the follow-up ultrasound examination. The results suggest that the B-ultrasound-guided Mammotome system may be an efficient tool for the diagnosis and treatment of impalpable breast lesions.

Entities:  

Mesh:

Year:  2008        PMID: 18835778     DOI: 10.1016/j.breast.2008.08.004

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  9 in total

1.  Feasibility and safety of image-guided vacuum-assisted breast biopsy: A PRISMA-compliant systematic review and meta-analysis of 20 000 population from 36 longitudinal studies.

Authors:  Ming Fang; Guilin Liu; Guoliang Luo; Tianyu Wu
Journal:  Int Wound J       Date:  2019-09-18       Impact factor: 3.315

2.  Ultrasound-guided vacuum-assisted breast biopsy using Mammotome biopsy system for detection of breast cancer: results from two high volume hospitals.

Authors:  Shaobo Pan; Wenguang Liu; Ketao Jin; Yu Liu; Yunxiao Zhou
Journal:  Int J Clin Exp Med       Date:  2014-01-15

Review 3.  Status quo and development trend of breast biopsy technology.

Authors:  Yan-Jun Zhang; Lichun Wei; Jie Li; Yi-Qiong Zheng; Xi-Ru Li
Journal:  Gland Surg       Date:  2013-02

4.  Completely removing solitary intraductal papillomas using the Mammotome system guided by ultrasonography is feasible and safe.

Authors:  Wenjun Yi; Feng Xu; Qiongyan Zou; Zhonghua Tang
Journal:  World J Surg       Date:  2013-11       Impact factor: 3.352

5.  Ultrasound-guided diagnostic breast biopsy methodology: retrospective comparison of the 8-gauge vacuum-assisted biopsy approach versus the spring-loaded 14-gauge core biopsy approach.

Authors:  Stephen P Povoski; Rafael E Jimenez; Wenle P Wang
Journal:  World J Surg Oncol       Date:  2011-08-11       Impact factor: 2.754

6.  Clinical Value of Ultrasound-Guided Minimally Invasive Biopsy in the Diagnosis or Treatment of Breast Nodules.

Authors:  Yan-Hong Gao; Shi-Cong Zhu; Ya Xu; Shun-Ji Gao; Yu Zhang; Qun-An Huang; Wen-Hong Gao; Jian Zhu; Hui-Juan Xiang; Xu-Hui Gao
Journal:  Cancer Manag Res       Date:  2020-12-23       Impact factor: 3.989

7.  Vacuum-Assisted Excision, Scarless Solution for Fibroadenoma Breast-A Single-Center Experience.

Authors:  R Rupa; Suchana Kushvaha
Journal:  Indian J Radiol Imaging       Date:  2021-11-01

8.  Ultrasound-guided vacuum-assisted core biopsy in the diagnosis and treatment of focal lesions of the breast - own experience.

Authors:  Wojciech Kibil; Diana Hodorowicz-Zaniewska; Antoni Szczepanik; Jan Kulig
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2012-11-09       Impact factor: 1.195

9.  Mammotome® biopsy system for the resection of breast lesions: Clinical experience in two high-volume teaching hospitals.

Authors:  Yangping Jiang; Huanrong Lan; Qian Ye; Ketao Jin; Min Zhu; Xiaoyan Hu; Lisong Teng; Feilin Cao; Xianfang Lin
Journal:  Exp Ther Med       Date:  2013-07-01       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.